Abstract
Aim:
Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
Methods:
We identified seven SNP(single nucleotidepolymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction).
Results:
Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups.
Conclusion:
Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
Similar content being viewed by others
Article PDF
References
Hyman SE . The NIMH perspective: next steps in schizophrenia research. Biol Psychiatry 2000b; 47: 1–7.
Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105–19.
Werge T, Elbaek Z, Andersen MB, Lundbaek JA, Rasmussen HB . Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans. Pharmacogenomics J 2003; 3: 97–100.
Liou YJ, Liao DL, Chen JY, Wang YC, Lin CC, Bai YM, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004; 5: 243–51.
Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J . Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695–705.
Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenia patients. Pharmacogenetics 2001; 11: 545–50.
Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Ono S, Otani K, et al. Relationship between TaqIA dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001; 105: 271–4.
Arinami T, Gao M, Hamaguchi H, Toru M . A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577–82.
Cravchik A, Sibley DR, Gejman PV . Analysis of neuroleptic binding affinities and potencies for the difference human D2 dopamine receptor missense variants. Pharmacogenetics 1999; 9: 17–23.
Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005; 376: 1–4.
Casey DE . Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10: 105–14.
Farde L, Nordstrom AL . PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychopharmacol Ser 1993; 10: 94–100.
Farde L, Hall H, Pauli S, Halldin C . Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 1995; 20: 200–8.
Farde L, Mack RJ, Nyberg S, Halldin C . D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psycho-pharmacol 1997; 12: S3–7.
Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997; 133: 396–404.
Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S . The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57: PL 103–7.
Karbe H, Wienhard K, Hamacher K, Huber M, Herholz K, Coenen HH, et al. Positron emission tomography with (18F) methyl-spiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991; 86: 163–73.
Kapur S, Zipursky R, Jones C, Remington G, Houle S . Relationship between dopamine D2 occupancy clinical response, and side effects: a double-blind PET study of first-Episode schizophrenia. Am J Psychiatry 2000; 157: 514–20.
Spitzer RL, Williams JB, Gibbon M, First MB . The structured clinical interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 1992; 49: 624–9.
Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, et al. The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res 2004; 67: 75–85.
Jonsson EG, Nothen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, et al. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 1999; 40: 31–6.
Sham PC, Curtis D . Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105.
Lewontin RC . The interaction of selection and linkage. II. Optimum models Genetics 1964; 50: 757–82.
Zapata C, Carollo C, Rodriguez S . Sampling variance and distribution of the D' measure of overall gametic disequilibrium between multiallelic loci. Ann Hum Genet 2001; 65: 395–406.
Xie X . Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet 1993; 53: 1107.
Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003; 117: 57–60.
Mihara K, Suzuki A, Kondo T, Nagashima U, Ono S, Otani K, et al. No relationship between TaqI a polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. Am J Med Genet 2000; 96: 422–4.
Mihara K, Kondo T, Suzuki A, Yasui N, Ono S, Otani K, et al. No relationship between -141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenia patients: a preliminary study. Psychiatry Res 2001; 101: 33–8.
Chen CH, Wei FC, Koong FJ, Hsiao KJ . Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from the national 973 and 863 programs, the National Natural Science Foundation of China, and the Shanghai Municipal Commission for Science and Technology.
Rights and permissions
About this article
Cite this article
Wu, Sn., Gao, R., Xing, Qh. et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 27, 966–970 (2006). https://doi.org/10.1111/j.1745-7254.2006.00355.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00355.x
Keywords
This article is cited by
-
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Signal Transduction and Targeted Therapy (2023)
-
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes
The Pharmacogenomics Journal (2016)
-
An Association Study on the Polymorphisms of Dopaminergic Genes with Working Memory in a Healthy Chinese Han Population
Cellular and Molecular Neurobiology (2012)
-
Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients
Psychopharmacology (2012)
-
Epigenetics and Biomarkers in the Staging of Neuropsychiatric Disorders
Neurotoxicity Research (2010)